Neutrophil to lymphocyte ratio predicts cardiovascular events in people with type 2 diabetes: Post hoc analysis of the SUSTAIN 6 and PIONEER 6 cardiovascular outcomes trials

Diabetes Obes Metab. 2023 Aug;25(8):2398-2401. doi: 10.1111/dom.15088. Epub 2023 May 8.

¹ St. Michael's Hospital of Unity Health Toronto, Toronto, Ontario, Canada.
² Ted Rogers Centre for Heart Research, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
³ Novo Nordisk A/S, Søborg, Denmark.
⁴ Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
⁵ Clinical Research, Steno Diabetes Center Copenhagen, University of Copenhagen, Herlev, Denmark.
⁶ Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
⁷ Brigham and Women's Hospital, Boston, Massachusetts, USA.

No abstract available

Keywords: GLP-1 analogue; antidiabetic drug; cardiovascular disease; randomized trial; type 2 diabetes.

Publication types